These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21411111)

  • 21. Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study.
    Mo D; Blum WF; Rosilio M; Webb SM; Qi R; Strasburger CJ
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4581-8. PubMed ID: 25233155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H).
    Rosilio M; Blum WF; Edwards DJ; Shavrikova EP; Valle D; Lamberts SW; Erfurth EM; Webb SM; Ross RJ; Chihara K; Henrich G; Herschbach P; Attanasio AF
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1684-93. PubMed ID: 15070931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN; Kandemir N
    Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life in transition phase in adolescents and young adults with severe and partial growth hormone deficiency.
    Oswiecimska JM; Roczniak W; Romanowicz D; Szymlak A; Mikolajczak A; Malczyk Z; Stojewska M; Ziora KT
    Neuro Endocrinol Lett; 2014; 35(8):676-83. PubMed ID: 25702295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B; Kann PH
    Med Klin (Munich); 2004 Oct; 99(10):569-77. PubMed ID: 15490072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy.
    Ragnar Agnarsson H; Johannsson G; Ragnarsson O
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1479-85. PubMed ID: 24423362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption.
    Svensson J; Mattsson A; Rosén T; Wirén L; Johannsson G; Bengtsson BA; Koltowska Häggström M;
    Growth Horm IGF Res; 2004 Jun; 14(3):207-15. PubMed ID: 15125882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency.
    Hoybye C; Jönsson P; Monson JP; Koltowska-Häggström M; Hána V; Geffner M; Abs R
    Eur J Endocrinol; 2007 Nov; 157(5):589-96. PubMed ID: 17984238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The "quality of life-assessment of growth hormone deficiency in adults" questionnaire: can it be used to assess quality of life in hypopituitarism?
    Barkan AL
    J Clin Endocrinol Metab; 2001 May; 86(5):1905-7. PubMed ID: 11344182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
    Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults.
    Gilchrist FJ; Murray RD; Shalet SM
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):363-70. PubMed ID: 12201829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency.
    Giavoli C; Profka E; Verrua E; Ronchi CL; Ferrante E; Bergamaschi S; Sala E; Malchiodi E; Lania AG; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3983-8. PubMed ID: 22904173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposal of a clinical response score and predictors of clinical response to 2 years of GH replacement therapy in adult GH deficiency.
    Schneider HJ; Buchfelder M; Wallaschofski H; Luger A; Johannsson G; Kann PH; Mattsson A
    Eur J Endocrinol; 2015 Dec; 173(6):843-51. PubMed ID: 26369579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.
    Yuen KC; Koltowska-Häggström M; Cook DM; Fox JL; Jönsson PJ; Geffner ME; Abs R
    Eur J Endocrinol; 2013 Oct; 169(4):511-9. PubMed ID: 23904277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency.
    Elbornsson M; Götherström G; Franco C; Bengtsson BÅ; Johannsson G; Svensson J
    Eur J Endocrinol; 2012 Feb; 166(2):181-9. PubMed ID: 22106341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
    Underwood LE; Attie KM; Baptista J;
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5273-80. PubMed ID: 14602761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.